Cargando…

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients

INTRODUCTION: Rheumatoid arthritis is a systemic inflammatory disease, and classical disease-modifying antirheumatic drugs (cDMARDs) have proven efficacy. It is unknown what impact cDMARDs might have on dementia as an outcome. METHODS: Incident diagnoses of rheumatoid arthritis in persons over 18 ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Judge, Andy, Garriga, Cesar, Arden, Nigel K., Lovestone, Simon, Prieto-Alhambra, Dani, Cooper, Cyrus, Edwards, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700830/ https://www.ncbi.nlm.nih.gov/pubmed/29201995 http://dx.doi.org/10.1016/j.trci.2017.10.002

Ejemplares similares

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
por: Hawley, Samuel, et al.
Publicado: (2019)

The impact of rheumatoid arthritis on the risk of adverse events following joint replacement: a real-world cohort study
por: Burn, Edward, et al.
Publicado: (2018)

The effect of rheumatoid arthritis on patient-reported outcomes following knee and hip replacement: evidence from routinely collected data
por: Burn, Edward, et al.
Publicado: (2019)

Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
por: Prieto-Alhambra, Daniel, et al.
Publicado: (2011)

Geographical Variation in Outcomes of Primary Hip and Knee Replacement
por: Garriga, Cesar, et al.
Publicado: (2019)

Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications
por: Kern, David M., et al.
Publicado: (2019)

Assessment on patient outcomes of primary hip replacement: an interrupted time series analysis from ‘The National Joint Registry of England and Wales’
por: Garriga, Cesar, et al.
Publicado: (2019)

Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study
por: Hawley, Samuel, et al.
Publicado: (2016)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

UK podiatrists’ experiences of podiatry services for people living with arthritis: a qualitative investigation
por: McCulloch, Louise, et al.
Publicado: (2018)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Impact of Rheumatoid Arthritis and Its Management on Falls, Fracture and Bone Mineral Density in UK Biobank
por: Clynes, Michael A., et al.
Publicado: (2019)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
por: Fazeli, Mir Sohail, et al.
Publicado: (2021)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Mortality rates at 10 years after metal-on-metal hip resurfacing compared with total hip replacement in England: retrospective cohort analysis of hospital episode statistics
por: Kendal, Adrian R, et al.
Publicado: (2013)

Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents
por: Desai, Rishi J., et al.
Publicado: (2022)

Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study
por: Newby, Danielle, et al.
Publicado: (2020)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database
por: Khalid, Sara, et al.
Publicado: (2018)

Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014
por: Burn, Edward, et al.
Publicado: (2018)

Lifetime risk of knee and hip replacement following a diagnosis of RA: findings from a cohort of 13 961 patients from England
por: Burn, Edward, et al.
Publicado: (2019)

Lifetime risk of knee and hip replacement following a diagnosis of RA: findings from a cohort of 13 961 patients from England
por: Burn, Edward, et al.
Publicado: (2019)

Within-subject foot motion variability in patients with Rheumatoid Arthritis
por: Hooper, Lindsey, et al.
Publicado: (2010)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Plasma proteins predict conversion to dementia from prodromal disease
por: Hye, Abdul, et al.
Publicado: (2014)

Evidence for current recommendations concerning the management of foot health for people with chronic long-term conditions: a systematic review
por: Edwards, Katherine, et al.
Publicado: (2017)

Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera
por: Matsuno, H, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_5qp86ifhimbcv7s8cuhgss6qon